This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Biosimilar Etanercept (Mycenax)

Mycenax Biotech Inc.

Drug Names(s): Biosimilar Enbrel, ENIA11, ENIA 11, ENIA-11, BT-D001, BTD001, BTD 001

Description: Mycenax's compound is a biosimilar form of etanercept (Enbrel).

Enbrel is a recombinant protein with properties of a monoclonal antibody. It is a fusion protein of the Fc (constant region) of a human antibody grafted to the ligand-binding portion of the human TNF receptor. The TNF receptor part of Enbrel functionally substitutes for an anti-TNF antibody. Blocking the activity of TNF impacts both autoimmunity and the immune response to pathogens.

Deal Structure: Mycenax and TSH Biopharm
Mycenax and TSH Biopharm have a worldwide agreement to jointly develop biologic drugs.


Biosimilar Etanercept (Mycenax) News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug